Skip to main content

What does it mean for you?

Esperoct® is an injectable extended half-life (EHL) for hemophilia A. Compared with standard half-life products it may require fewer infusions and offers higher factor levels.

What does it mean for you?

Esperoct® is an injectable extended half-life (EHL) for hemophilia A. Compared with standard half-life products it may require fewer infusions and offers higher factor levels.

factor VIII product.a

Esperoct® has a 22-hour average half-life in adultsb.

Because Esperoct® lasts longerc, you may not need to infuse as often, saving time in your busy schedule.

aCompared with the half-lives in the Prescribing Information of other recombinant FVIII products.

bData shown are from 42 adults who received a pharmacokinetic (PK) assessment around the first Esperoct® 50 IU/kg dose.

cCompared with SHL Products.

for longer.

Esperoct® keeps factor levels at or above 3% (moderate hemophilia) for 100% of the time in people 12 years or older who treat prophylactically.d,e,f

A switch from standard half-life treatment to Esperoct® means factor levels remain high from one dose to the next.

dFactor activity between 1%-5% is defined as moderate hemophilia.

eTrough level goal is 1% for prophylaxis.

fData shown are from a study where 175 previously treated adolescents and adults received routine prophylaxis with Esperoct® 50 IU/kg every 4 days for 76 weeks. Pre-dose factor activity (trough) levels were evaluated at follow-up visits. Mean trough levels for adolescents (12-<18 years) were 2.7 IU/dL.

from bleeds.

Headline

In the main phase of the pivotal trial for adults and adolescents, results show 1.2 ABR overall bleeds per year, 0.9 joint bleeds per year, and 0 spontaneous/traumatic bleeds.g After being treated with Esperoct® for up to 6.6 years, people 12 years and older in the long-term trial, including main and extension phases, saw an overall bleed rate of 0.8 per year.h
 

 

g175 PTPs with severe hemophilia A received Esperoct® 50 IU/kg every 4 days for 76 weeks based on median annualized bleed rates shown.

hMedian annualized bleeding rate shown is from the main and extension phases of the pivotal clinical trial of previously treated people aged ≥12 years with severe hemophilia A who received Esperoct® 50 IU/kg every 4 days, for up to 6.6 years.

can take the heat.

With Esperoct®, factor can be stored from 86˚F up to 104˚F for up to 3 months, opening the door to more of life's adventures.i


i
or 86˚F for up to 12 months and up to 4 hours after reconstitution.

Esperoct® package and syringe

Take the

treatment personality quiz!

Do you love a good plan? Or seeing where the road takes you? Your answer may help you find ways to manage hemophilia A that work best for you. Take our quiz to discover your “treatment personality type”!
 



Switch to

dosing made simple.

A standard 50 IU/kg dose makes
starting or switching to Esperoct® easy. 

Get the

support you need.

Struggling with insurance issues, connecting to community, or getting the product information you need? Here are resources that can help.

Selected Important Safety Information

Who should not use Esperoct®?
  • You should not use Esperoct® if you are allergic to factor VIII or any of the other ingredients of Esperoct® or if you are allergic to hamster proteins
What is the most important information I need to know about Esperoct®?
  • Do not attempt to do an infusion yourself unless you have been taught how by your healthcare provider or hemophilia treatment center
  • Call your healthcare provider right away or get emergency treatment right away if you get any signs of an allergic reaction, such as: hives, chest tightness, wheezing, dizziness, difficulty breathing, and/or swelling of the face

What is Esperoct®?

Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] is an injectable medicine to treat and prevent or reduce the number of bleeding episodes in people with hemophilia A. Your healthcare provider may give you Esperoct® when you have surgery

  • Esperoct® is not used to treat von Willebrand Disease

Important Safety Information

Who should not use Esperoct®?
  • You should not use Esperoct® if you are allergic to factor VIII or any of the other ingredients of Esperoct® or if you are allergic to hamster proteins
What is the most important information I need to know about Esperoct®?
  • Do not attempt to do an infusion yourself unless you have been taught how by your healthcare provider or hemophilia treatment center
  • Call your healthcare provider right away or get emergency treatment right away if you get any signs of an allergic reaction, such as: hives, chest tightness, wheezing, dizziness, difficulty breathing, and/or swelling of the face
What should I tell my healthcare provider before using Esperoct®?
  • Before taking Esperoct®, you should tell your healthcare provider if you have or have had any medical conditions, take any medicines (including non-prescription medicines and dietary supplements), are nursing, pregnant or planning to become pregnant, or have been told that you have inhibitors to factor VIII
  • Your body can make antibodies called “inhibitors” against Esperoct®, which may stop Esperoct® from working properly. Call your healthcare provider right away if your bleeding does not stop after taking Esperoct®
What are the possible side effects of Esperoct®?
  • Common side effects of Esperoct® include rash or itching, and swelling, pain, rash or redness at the location of infusion

Please click here for Prescribing Information.

Esperoct® is a prescription medication.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.